Abstract

Oral formulations include anti-viral agents. These oral formulations are manufactured in various permutations such as a chewing gum or lozenge which incorporate anti-viral agents for protecting an individuals body from viruses.

IPC Classes  ?

• A61K 9/00 - Medicinal preparations characterised by special physical form
• A61K 9/68 - Medicinal preparations characterised by special physical form chewing gum type
• A61K 9/20 - Pills, lozenges or tablets
• A61K 45/06 - Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
• A61K 31/55 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
• A61K 31/401 - ProlineDerivatives thereof, e.g. captopril
• A61K 31/675 - Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
• A61K 31/472 - Non-condensed isoquinolines, e.g. papaverine
• A61K 31/722 - ChitinChitosan
• A61K 33/30 - ZincCompounds thereof
• A61K 33/18 - IodineCompounds thereof
• A61K 31/155 - Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (HN=C(OH)NH2), isothiourea (HN=C(SH)—NH2)
• A61K 31/44 - Non-condensed pyridinesHydrogenated derivatives thereof
• A61K 31/7016 - Disaccharides, e.g. lactose, lactulose
• A61K 36/59 - Menispermaceae (Moonseed family), e.g. hyperbaena or coralbead
• A61K 31/49 - Cinchonan derivatives, e.g. quinine
• A61K 31/79 - Polymers of vinyl pyrrolidone
• A61K 33/40 - Peroxides
• A61K 38/16 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof
• A61K 31/724 - Cyclodextrins

Abstract

Oral formulations include anti-viral agents. These oral formulations are manufactured in various permutations such as a chewing gum or lozenge which incorporate anti-viral agents for protecting an individual's body from viruses.

IPC Classes  ?

• A61P 31/00 - Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
• A61P 9/14 - VasoprotectivesAntihaemorrhoidalsDrugs for varicose therapyCapillary stabilisers
• A61K 47/26 - Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharidesDerivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
• A61K 9/00 - Medicinal preparations characterised by special physical form

Abstract

An improved method for manufacture of chewing gums containing active ingredient(s) that preserves the efficacy of the active ingredient(s) by avoiding exposure to high heat and extreme cold during milling that can otherwise degrade the active's efficacy. A chewing gum base is used, along with one or more therapeutically-active ingredients, one or more sweeteners (alcohol-based and/or natural), and one or more flavorings and optional flavor modifiers. The method generally comprises heating the gum base in ovens to melt the gum base. Separately, the active ingredient(s), sweeteners and flavorings are combined in a mixer. The melted gum base is added to the mixer and cools to produce a particulate mixture. As mixing continues the mass cools to room temperature and forms granular pieces. The granular pieces are ground into a powder at room temperature, mixed at room temperature with tableting excipients, and tableted. Several variations on the foregoing are also described.

IPC Classes  ?

• A61K 9/68 - Medicinal preparations characterised by special physical form chewing gum type
• A61K 31/522 - Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
• A61K 31/722 - ChitinChitosan
• A61K 31/05 - Phenols
• A61K 36/185 - Magnoliopsida (dicotyledons)
• A61K 47/26 - Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharidesDerivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin

Abstract

Oral formulations include a polysaccharide, such as, chitosan and an anthoeyanin-rich extract from dark berries. These oral formulations are manufactured in various permutations such as a chewing gum or lozenge which incorporate chitosan and berry extract powder for protecting the oral cavity from the bacteria that cause gingivitis and periodontitis.

IPC Classes  ?

• A61K 9/68 - Medicinal preparations characterised by special physical form chewing gum type
• A61K 9/00 - Medicinal preparations characterised by special physical form
• A61K 9/28 - DrageesCoated pills or tablets
• A61K 31/722 - ChitinChitosan
• A61K 36/00 - Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
• A61K 36/73 - Rosaceae (Rose family), e.g. strawberry, chokeberry, blackberry, pear or firethorn
• A61K 47/10 - AlcoholsPhenolsSalts thereof, e.g. glycerolPolyethylene glycols [PEG]PoloxamersPEG/POE alkyl ethers
• A61P 1/02 - Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis

Abstract

Oral formulations include a polysaccharide, such as, chitosan and an anthoeyanin-rich extract from dark berries. These oral formulations are manufactured in various permutations such as a chewing gum or lozenge which incorporate chitosan and berry extract powder for protecting the oral cavity from the bacteria that cause gingivitis and periodontitis.

IPC Classes  ?

• A24B 15/30 - Treatment of tobacco products or tobacco substitutes by chemical substances by organic substances
• A24F 47/00 - Smokers’ requisites not otherwise provided for
• A61K 31/352 - Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. cannabinols, methantheline

Abstract

Oral formulations include a polysaccharide, such as, chitosan and an anthocyanin-rich extract from dark berries. These oral formulations are manufactured in various permutations such as a chewing gum or lozenge which incorporate chitosan and berry extract powder for protecting the oral cavity from the bacteria that cause gingivitis and periodontitis.

IPC Classes  ?

• A61K 9/68 - Medicinal preparations characterised by special physical form chewing gum type
• A61K 47/46 - Ingredients of undetermined constitution or reaction products thereof, e.g. skin, bone, milk, cotton fibre, eggshell, oxgall or plant extracts
• A61K 47/26 - Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharidesDerivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
• A61K 47/14 - Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
• A61K 47/38 - CelluloseDerivatives thereof
• A61K 45/06 - Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
• A61K 31/722 - ChitinChitosan
• A61K 36/73 - Rosaceae (Rose family), e.g. strawberry, chokeberry, blackberry, pear or firethorn
• A61P 29/00 - Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agentsNon-steroidal antiinflammatory drugs [NSAID]

Abstract

Oral compositions provide delivery of cannabinoids to a subject. The oral compare chewable, fast- or slow-dissolving once placed in the mouth of a subject.

IPC Classes  ?

• A61K 31/352 - Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. cannabinols, methantheline
• A61K 31/05 - Phenols
• A61K 36/185 - Magnoliopsida (dicotyledons)
• A61K 9/20 - Pills, lozenges or tablets
• A61K 9/00 - Medicinal preparations characterised by special physical form
• A61K 9/68 - Medicinal preparations characterised by special physical form chewing gum type
• A61K 31/70 - CarbohydratesSugarsDerivatives thereof
• A61K 47/10 - AlcoholsPhenolsSalts thereof, e.g. glycerolPolyethylene glycols [PEG]PoloxamersPEG/POE alkyl ethers
• A61K 47/24 - Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
• A61K 47/36 - PolysaccharidesDerivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin

Abstract

Oral compositions provide delivery of cannabinoids to a subject. The oral compare chewable, fast- or slow-dissolving once placed in the mouth of a subject.

IPC Classes  ?

• A61K 31/352 - Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. cannabinols, methantheline
• A61K 31/05 - Phenols
• A61K 36/185 - Magnoliopsida (dicotyledons)
• A61K 9/20 - Pills, lozenges or tablets
• A61K 9/00 - Medicinal preparations characterised by special physical form
• A61K 9/68 - Medicinal preparations characterised by special physical form chewing gum type
• A61K 31/70 - CarbohydratesSugarsDerivatives thereof
• A61K 47/10 - AlcoholsPhenolsSalts thereof, e.g. glycerolPolyethylene glycols [PEG]PoloxamersPEG/POE alkyl ethers
• A61K 47/24 - Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
• A61K 47/36 - PolysaccharidesDerivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin

Abstract

An improved method for manufacture of chewing gums containing active ingredient(s) that preserves the efficacy of the active ingredient(s) by avoiding exposure to high heat and extreme cold during milling that can otherwise degrade the active's efficacy. A chewing gum base is used, along with one or more therapeutically-active ingredients, one or more sweeteners (alcohol-based and/or natural), and one or more flavorings and optional flavor modifiers. The method generally comprises heating the gum base in ovens to melt the gum base. Separately, the active ingredient(s), sweeteners and flavorings are combined in a mixer. The melted gum base is added to the mixer and cools to produce a particulate mixture. As mixing continues the mass cools to room temperature and forms granular pieces. The granular pieces are ground into a powder at room temperature, mixed at room temperature with tableting excipients, and tableted. Several variations on the foregoing are also described.

IPC Classes  ?

• A61K 9/68 - Medicinal preparations characterised by special physical form chewing gum type
• A61K 31/352 - Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. cannabinols, methantheline
• A61K 31/05 - Phenols
• A61K 31/522 - Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
• A61K 36/185 - Magnoliopsida (dicotyledons)
• A61K 31/722 - ChitinChitosan
• A23G 4/10 - Chewing gum characterised by the composition characterised by the carbohydrates used, e.g. polysaccharides
• A23G 4/08 - Chewing gum characterised by the composition of the chewing gum base
• A23G 4/06 - Chewing gum characterised by the composition
• A23G 4/12 - Chewing gum characterised by the composition containing microorganisms or enzymesChewing gum characterised by the composition containing paramedical or dietetical agents, e.g. vitamins
• A23G 4/18 - Chewing gum characterised by shape, structure or physical form, e.g. aerated products

Abstract

An improved method for manufacture of chewing gums containing active ingredient(s) that preserves the efficacy of the active ingredient(s) by avoiding exposure to high heat and extreme cold during milling that can otherwise degrade the active's efficacy. A chewing gum base is used, along with one or more therapeutically-active ingredients, one or more sweeteners (alcohol-based and/or natural), and one or more flavorings and optional flavor modifiers. The method generally comprises heating the gum base in ovens to melt the gum base. Separately, the active ingredient(s), sweeteners and flavorings are combined in a mixer. The melted gum base is added to the mixer and cools to produce a particulate mixture. As mixing continues the mass cools to room temperature and forms granular pieces. The granular pieces are ground into a powder at room temperature, mixed at room temperature with tableting excipients, and tableted. Several variations on the foregoing are also described.

IPC Classes  ?

• A61K 9/68 - Medicinal preparations characterised by special physical form chewing gum type
• A23G 4/10 - Chewing gum characterised by the composition characterised by the carbohydrates used, e.g. polysaccharides
• A23G 4/08 - Chewing gum characterised by the composition of the chewing gum base
• A61K 31/352 - Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. cannabinols, methantheline
• A61K 31/05 - Phenols
• A23G 4/06 - Chewing gum characterised by the composition
• A23G 4/12 - Chewing gum characterised by the composition containing microorganisms or enzymesChewing gum characterised by the composition containing paramedical or dietetical agents, e.g. vitamins
• A61K 31/522 - Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
• A61K 31/722 - ChitinChitosan
• A61K 36/185 - Magnoliopsida (dicotyledons)
• A23G 4/18 - Chewing gum characterised by shape, structure or physical form, e.g. aerated products

Abstract

An improved method for manufacture of chewing gums containing active ingredient(s) that preserves the efficacy of the active ingredient(s) by avoiding exposure to high heat and extreme cold during milling that can otherwise degrade the active's efficacy. A chewing gum base is used, along with one or more therapeutically-active ingredients, one or more sweeteners (alcohol-based and/or natural), and one or more flavorings and optional flavor modifiers. The method generally comprises heating the gum base in ovens to melt the gum base. Separately, the active ingredient(s), sweeteners and flavorings are combined in a mixer. The melted gum base is added to the mixer and cools to produce a particulate mixture. As mixing continues the mass cools to room temperature and forms granular pieces. The granular pieces are ground into a powder at room temperature, mixed at room temperature with tableting excipients, and tableted. Several variations on the foregoing are also described.

IPC Classes  ?

• A61K 31/352 - Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. cannabinols, methantheline
• A61K 31/05 - Phenols
• A23G 4/06 - Chewing gum characterised by the composition
• A23G 4/08 - Chewing gum characterised by the composition of the chewing gum base
• A23G 4/18 - Chewing gum characterised by shape, structure or physical form, e.g. aerated products
• A23G 4/10 - Chewing gum characterised by the composition characterised by the carbohydrates used, e.g. polysaccharides
• A61K 9/68 - Medicinal preparations characterised by special physical form chewing gum type
• A23G 4/12 - Chewing gum characterised by the composition containing microorganisms or enzymesChewing gum characterised by the composition containing paramedical or dietetical agents, e.g. vitamins